Showing results (61-70 of 102) with videos related to

Sort By:
Pageof 11
Cancer Biology & Therapy|December 30, 2009
Sorafenib inhibits ERK1/2 and MCL-1(L) phosphorylation levels resulting in caspase-independent cell death in malignant pleural mesotheliomaSharyn I Katz, Lanlan Zhou, Grace Chao, et al.
Elife|July 29, 2021
A subset of CB002 xanthine analogs bypass p53-signaling to restore a p53 transcriptome and target an S-phase cell cycle checkpoint in tumors with mutated-p53Liz Hernandez Borrero, David T Dicker, John Santiago, et al.
American Journal of Cancer Research|October 18, 2021
Potent preclinical sensitivity to imipridone-based combination therapies in oncohistone H3K27M-mutant diffuse intrinsic pontine glioma is associated with induction of the integrated stress response, TRAIL death receptor DR5, reduced ClpX and apoptosisRobyn Borsuk, Lanlan Zhou, Wen-I Chang, et al.
Cell Cycle (Georgetown, Tex.)|August 17, 2012
Mitomycin C potentiates TRAIL-induced apoptosis through p53-independent upregulation of death receptors: evidence for the role of c-Jun N-terminal kinase activationHairong Cheng, Bo Hong, Lanlan Zhou, et al.
American Journal of Cancer Research|March 9, 2022
Preclinical studies with ONC201/TIC10 and lurbinectedin as a novel combination therapy in small cell lung cancer (SCLC)Nicholas R Liguori, Ashley Sanchez Sevilla Uruchurtu, Leiqing Zhang, et al.
Disease Markers|May 7, 2015
The relationship between clinical feature, complex immunophenotype, chromosome karyotype, and outcome of patients with acute myeloid leukemia in ChinaBingjie Ding, Lanlan Zhou, Xuejie Jiang, et al.
Arthritis Research & Therapy|October 13, 2021
Correlation of peripheral CD4+GranzB+CTLs with disease severity in patients with primary Sjögren's syndromeQi Wang, Nan Che, Chengyin Lu, et al.
Oncotarget|November 4, 2020
TRAIL receptor agonists convert the response of breast cancer cells to ONC201 from anti-proliferative to apoptoticMarie D Ralff, Aakash Jhaveri, Jocelyn E Ray, et al.
American Journal of Cancer Research|January 13, 2025
Synergistic combination therapy with ONC201 or ONC206, and enzalutamide or darolutamide in preclinical studies of castration-resistant prostate cancerLaura Jinxuan Wu, Maximilian Pinho-Schwermann, Lanlan Zhou, et al.
Plos One|January 14, 2014
Identification of novel molecular markers for prognosis estimation of acute myeloid leukemia: over-expression of PDCD7, FIS1 and Ang2 may indicate poor prognosis in pretreatment patients with acute myeloid leukemiaYiming Tian, Zoufang Huang, Zhixiang Wang, et al.
Pageof 11